Welcome to our dedicated page for Haemonetics Mass SEC filings (Ticker: HAE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Haemonetics Corporation filings document current-report disclosures for a Massachusetts medical technology company focused on hospital, plasma collection and blood center products. Recent Form 8-K filings cover quarterly and annual operating results, furnished earnings releases, and Regulation FD disclosures related to corporate responsibility reporting and capital-structure events.
The company’s filings also record governance and board matters, including director and committee disclosures tied to annual meeting processes. Material-event reports document financing and corporate actions such as repayment of convertible senior notes and the completed acquisition of Vivasure Medical Limited, a percutaneous vessel closure technology company.
Haemonetics Corporation is asking shareholders to elect eight directors, approve advisory say‑on‑pay, ratify Ernst & Young as auditor, and update its long‑term incentive and employee stock purchase plans at the 2026 Annual Meeting on July 24 in Boston.
The proxy highlights strong fiscal 2026 results: revenue of $1.334 billion, adjusted EPS of $4.96, free cash flow of $209.9 million and adjusted operating margin of 25.4%, including 9.5% organic ex‑CSL revenue growth and a 45.2% free cash flow increase. It notes robust shareholder support, with approximately 98.6% approval of 2026 executive pay, and explains a pay‑for‑performance program using cash bonuses tied to revenue, EPS and free cash flow plus PSU, RSU and option awards. The filing also details an independent, skills‑diverse board, a waiver of the age‑75 guideline to retain Board Chair Ellen Zane, strong governance practices such as majority voting and the right to call special meetings, and extensive shareholder outreach covering about 36% of shares.
Haemonetics Corp executive Maryanne Maunsell Farris, the VP and Chief Accounting Officer, reported an automatic share disposition tied to equity compensation. On the RSU vesting date, 259 shares of common stock were withheld at $71.28 per share to cover tax obligations, rather than sold on the open market. After this tax-withholding event, she beneficially owns 6,242 common shares, a figure that includes previously reported unvested restricted stock units.
Haemonetics Corp senior vice president of human resources Laurie A. Miller reported a small share disposition related to taxes. On the vesting of previously granted restricted stock units, 313 shares of common stock were withheld at a price of $71.28 per share to cover tax obligations. After this tax-withholding event, Miller directly holds 40,987 shares of Haemonetics common stock, which includes unvested restricted stock units.
Haemonetics Corporation is reorganizing how it reports its business segments. The company will move from three reportable segments to two, combining the Plasma and Blood Center segments into a single Apheresis segment and renaming the Hospital segment as MedSurg.
Haemonetics will begin reporting under this new structure with the first quarter of fiscal 2027, which began on March 29, 2026. To help comparison, it has posted a supplemental presentation with recast quarterly historical revenue for fiscal years 2024, 2025 and 2026, plus a recast of previously issued fiscal 2027 revenue guidance. The company explicitly states that this presentation does not reaffirm or update its fiscal 2027 guidance; any updates will come on the first quarter fiscal 2027 earnings call.
Haemonetics Corporation provides an overview of its global medical technology business in Plasma, Blood Center and Hospital segments, highlighting products that support plasma collection, blood management and hospital procedures.
The filing notes that Plasma and Hospital are viewed as the main long-term growth drivers, while Blood Center faces more challenging markets. In fiscal 2026, Plasma and Blood Center represented 39.3% and 16.6% of total revenue, and Hospital 44.1%. One Plasma customer generated 13% of total net revenues, and the ten largest customers accounted for 44%, underscoring customer concentration risk.
The company reports an aggregate market value of non‑affiliate equity of $2.23 billion as of September 27, 2025 and 45.4 million common shares outstanding as of May 15, 2026. Key themes include continued investment in R&D, new FDA clearances for NexSys PCS and VASCADE MVP XL, complex global regulatory obligations, supply chain and cybersecurity risks, and competition from large medtech peers across all business lines.
Haemonetics Corporation EVP and General Counsel Michelle L. Basil reported routine equity compensation activity. She received a grant of 28,424 restricted stock units, each convertible into one share of common stock, under the company’s 2019 long-term incentive plan. The RSUs vest over three years, with 40% vesting on each of the first two anniversaries of the grant date and 20% on the third.
The filing also shows 2,913 shares of common stock withheld at $56.29 per share to satisfy tax obligations tied to previously granted RSUs, which is not an open-market sale. After these transactions, she directly holds 40,405 shares of common stock, including unvested RSUs.
Haemonetics EVP and COO Frank Chan received an equity award and had shares withheld for taxes. On May 15, 2026, he was granted 27,535 restricted stock units (RSUs) under the company’s long-term incentive plan. Each RSU represents a right to receive one share of common stock when it vests.
The RSUs vest over three years, with 40% vesting on the first anniversary of the grant date, another 40% on the second anniversary, and the remaining 20% on the third anniversary. On the same date, 546 shares were disposed of at $56.29 per share to satisfy tax obligations related to vesting of previously granted RSUs, rather than through an open-market sale.
After these transactions, Chan directly owned 32,936 shares of Haemonetics common stock. This figure includes unvested RSUs and shares acquired through the Haemonetics Corporation 2007 Employee Stock Purchase Plan, including 139 shares bought on October 31, 2025 and 119 shares bought on April 30, 2026.
Haemonetics Corporation EVP and CFO James DArecca reported a new equity compensation grant. He received 29,312 shares of common stock in the form of restricted stock units (RSUs) at no cash cost, increasing his direct equity-based position.
In a related transaction, 2,505 shares were withheld at a market price of $56.29 per share to cover tax obligations tied to RSU vesting, which is not an open-market sale. After these transactions, he directly holds 25,132 shares, a figure that includes previously reported unvested RSUs.
The RSU award was granted under Haemonetics’ Amended and Restated 2019 Long-Term Incentive Compensation Plan. The units vest in three annual installments, with 40% vesting on each of the first two anniversaries of the grant date and the remaining 20% vesting on the third anniversary. Each RSU converts into one share of common stock upon vesting.
Haemonetics Corp VP and Chief Accounting Officer Maryanne Maunsell Farris received a grant of 2,220 restricted stock units, each representing one share of common stock vesting in three equal annual installments. In connection with RSU vesting, 197 shares were withheld to cover tax obligations, leaving her with 4,281 directly held shares, including unvested RSUs.